Fri, Aug 2, 12:32 PM (174 days ago)
RespireRx Pharmaceuticals Inc. entered into two material definitive agreements on July 29, 2024, with Alien Technology Transfer India Private Limited (ATT India) and Alien Technology Transfer USA Inc. (ATT US). These agreements supersede prior agreements dated July 2, 2024. Both agreements pertain to RespireRx's EndeavourRx’s GABAkines program. ATT India will assist in identifying and applying for appropriate NIH funding and targeted solicitations, with a focus on Phase II grants, which have a budget of $2,045,816 over 1-3 years. Fees are success-based, with a 10% success fee and additional support fees of $15,000 for Phase II. ATT US will provide TABA services, including regulatory affairs consulting and IP packages, contingent on entering a grant agreement. TABA fees are $50,000 for Phase II, with additional monthly fees ranging from $2,400 to $3,200. These agreements may impact RespireRx's financial position depending on the success of grant applications.